The nasal spray’s maker, AstraZeneca, has shipped only three lots, or about 758,000 doses, to the U.S. market, which is a fraction of what it supplied in earlier seasons.
AstraZeneca said the short supply resulted from difficulty producing viruses needed for two of the four components of the vaccine.
Read more here.
More articles on supply chain:
Prior authorizations making it ‘as difficult as possible’ for patients to get necessary medical supplies
Beaumont Health sells home medical equipment business
Cancer risk spurs new push to replace device sterilization technique
